ECSP14007644A - Composiciones intranasales de dexmedetomidina y métodos de uso de ellas - Google Patents

Composiciones intranasales de dexmedetomidina y métodos de uso de ellas

Info

Publication number
ECSP14007644A
ECSP14007644A ECIEPI20147644A ECPI201407644A ECSP14007644A EC SP14007644 A ECSP14007644 A EC SP14007644A EC IEPI20147644 A ECIEPI20147644 A EC IEPI20147644A EC PI201407644 A ECPI201407644 A EC PI201407644A EC SP14007644 A ECSP14007644 A EC SP14007644A
Authority
EC
Ecuador
Prior art keywords
dexmedetomidine
methods
intranasal compositions
intranasal
compositions
Prior art date
Application number
ECIEPI20147644A
Other languages
English (en)
Inventor
Geraldine A Henwood
Charles Alexander Freyer
Randall J Mack
Christopher T Sharr
Koleng, Jr
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48613351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14007644(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Publication of ECSP14007644A publication Critical patent/ECSP14007644A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0618—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee formulaciones intranasales que comprenden dexmedetomidina, o una sal farmacéuticamente aceptable de ella, y sus usos.
ECIEPI20147644A 2011-12-11 2014-07-02 Composiciones intranasales de dexmedetomidina y métodos de uso de ellas ECSP14007644A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161569255P 2011-12-11 2011-12-11
PCT/US2012/068988 WO2013090278A2 (en) 2011-12-11 2012-12-11 Intranasal dexmedetomidine compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
ECSP14007644A true ECSP14007644A (es) 2015-11-30

Family

ID=48613351

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20147644A ECSP14007644A (es) 2011-12-11 2014-07-02 Composiciones intranasales de dexmedetomidina y métodos de uso de ellas

Country Status (21)

Country Link
US (2) US9795559B2 (es)
EP (2) EP3406247A1 (es)
JP (2) JP6268100B2 (es)
KR (1) KR102190009B1 (es)
CN (1) CN104470516A (es)
AU (2) AU2012352528B9 (es)
BR (1) BR112014019171A8 (es)
CA (1) CA2858721C (es)
CL (1) CL2014001515A1 (es)
CO (1) CO7000773A2 (es)
CR (1) CR20140318A (es)
DO (1) DOP2014000123A (es)
EC (1) ECSP14007644A (es)
HK (1) HK1203049A1 (es)
IL (1) IL232977B (es)
MX (1) MX367286B (es)
PE (1) PE20142314A1 (es)
PH (1) PH12014501273A1 (es)
RU (1) RU2692245C2 (es)
SG (2) SG11201403094TA (es)
WO (1) WO2013090278A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9074079B2 (en) 2010-06-16 2015-07-07 Cargill, Incorporated Starch-based compositions for latex replacement
SG11201403094TA (en) * 2011-12-11 2014-10-30 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
WO2015044782A2 (en) * 2013-09-24 2015-04-02 Shin Nippon Biomedical Laboratories, Ltd. Intranasal dhe for the treatment of headache
CN105764496B (zh) 2013-10-07 2020-09-25 帝国制药美国公司 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物
FI3054934T3 (fi) * 2013-10-07 2024-07-19 Teikoku Pharma Usa Inc Menetelmät ja koostumukset vieroitusoireyhtymien hoitoon käyttäen ei-sedatiivisia transdermaalisia deksmedetomidiinikoostumuksia
TWI704933B (zh) 2013-10-07 2020-09-21 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
KR101831290B1 (ko) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
EP4371554A3 (en) 2016-12-31 2024-08-07 BioXcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
SG11202012772XA (en) * 2018-06-27 2021-01-28 Bioxcel Therapeutics Inc Film formulations containing dexmedetomidine and methods of producing them
CN109620802A (zh) * 2018-12-05 2019-04-16 杜皓 一种麻醉用鼻喷剂及其制备方法
CN111481506B (zh) * 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
CN116474218A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CN112107544A (zh) * 2019-06-28 2020-12-22 四川普锐特药业有限公司 右美托咪定鼻喷剂、其制备方法及应用
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN113827590A (zh) * 2020-06-08 2021-12-24 四川普锐特药业有限公司 右美托咪定在助眠药物制备中的应用
US20220226288A1 (en) * 2021-01-04 2022-07-21 Bioxcel Therapeutics, Inc. Dexmedetomidine treatment regimens
CN118217243A (zh) * 2021-03-29 2024-06-21 四川普锐特药业有限公司 一种增效防腐且兼顾低刺激性的右美托咪定鼻喷剂
CN113876776A (zh) * 2021-11-04 2022-01-04 江苏大学附属医院 一种复方鼻喷镇痛药剂及其制备方法
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
DK1516639T4 (en) 1990-12-05 2015-06-29 Gen Hospital Corp Use of NO to treat persistent pulmonary hypertension in newborns
GB9111732D0 (en) 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
US5713907A (en) 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
HU227939B1 (en) 1996-05-29 2012-06-28 Delsitech Oy Dissolvable oxides for biological applications
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
DE19749724A1 (de) 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
AR015744A1 (es) 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
ES2239466T3 (es) 1998-10-20 2005-09-16 Omeros Corporation Solucion de irrigacion y metodo de inhibicion del dolor y de la inflamacion.
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
AUPR184500A0 (en) 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
US6582457B2 (en) 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
WO2002089794A1 (en) 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US6864271B2 (en) 2002-11-12 2005-03-08 The Foundation For The Lsu Health Sciences Center Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
JP2006516262A (ja) * 2002-12-17 2006-06-29 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Ｙ２受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050058696A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20090117054A1 (en) 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
ES2624577T3 (es) 2006-02-13 2017-07-17 Orient Pharma (Samoa) Co. Ltd. Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea
GB0611241D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
US20080021074A1 (en) 2006-06-29 2008-01-24 Questcor Pharmaceuticals, Inc. Pharmaceutical Compositions and Related Methods of Treatment
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
CN101057830A (zh) 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法
US20090281156A1 (en) 2007-12-21 2009-11-12 Schering-Plough Healthcare Products, Inc, Enhancing photostabilization of oxymetazoline
AU2010248776B2 (en) * 2009-05-15 2013-06-06 Baudax Bio, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
AU2010281436B2 (en) 2009-07-27 2016-03-24 Tonix Pharma Limited. Methods for treatment of pain
NZ703808A (en) * 2010-01-08 2016-01-29 Recro Pharma Inc Topical transdermal dexmedetomidine compositions and methods of use thereof
SG11201403094TA (en) * 2011-12-11 2014-10-30 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof

Also Published As

Publication number Publication date
AU2012352528B2 (en) 2017-10-26
IL232977B (en) 2019-01-31
AU2012352528A1 (en) 2014-07-10
KR102190009B1 (ko) 2020-12-15
BR112014019171A8 (pt) 2017-07-11
CN104470516A (zh) 2015-03-25
IL232977A0 (en) 2014-07-31
MX2014006961A (es) 2014-09-22
RU2014128343A (ru) 2016-01-27
EP2787970A2 (en) 2014-10-15
US10682311B2 (en) 2020-06-16
US9795559B2 (en) 2017-10-24
US20180055764A1 (en) 2018-03-01
EP2787970A4 (en) 2015-10-28
BR112014019171A2 (es) 2017-06-20
US20130178465A1 (en) 2013-07-11
AU2012352528B9 (en) 2017-11-02
AU2018200591A1 (en) 2018-02-15
WO2013090278A3 (en) 2014-12-24
SG11201403094TA (en) 2014-10-30
NZ626999A (en) 2016-07-29
RU2692245C2 (ru) 2019-06-24
KR20140107329A (ko) 2014-09-04
CL2014001515A1 (es) 2014-12-05
HK1203049A1 (en) 2015-10-16
DOP2014000123A (es) 2014-12-31
WO2013090278A2 (en) 2013-06-20
JP2015513309A (ja) 2015-05-07
PH12014501273A1 (en) 2014-09-08
PE20142314A1 (es) 2015-01-23
CA2858721A1 (en) 2013-06-20
JP6268100B2 (ja) 2018-01-24
CR20140318A (es) 2014-10-28
CO7000773A2 (es) 2014-07-21
MX367286B (es) 2019-08-13
AU2018200591B2 (en) 2018-11-29
CA2858721C (en) 2021-03-16
JP2018030850A (ja) 2018-03-01
SG10201604653TA (en) 2016-07-28
EP2787970B1 (en) 2018-04-11
EP3406247A1 (en) 2018-11-28
JP6505177B2 (ja) 2019-04-24

Similar Documents

Publication Publication Date Title
ECSP14007644A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CR20140529A (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
CR20160419A (es) Nuevos compuestos biciclicos
CR20150462A (es) Inhibidores de erk y sus usos
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
DK2814504T3 (da) Protease inhibitor indeholdende sammensætninger, sammensætninger omfattende samme og metoder til fremstilling og brug af samme
UY34418A (es) Compuestos derivados de la piridopiracina, su preparación, composiciones que los contienen y su uso en terapia
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
CO7020867A2 (es) Formulaciones de anticuerpo y metodos
BR112012031906A2 (pt) métodos e composições para modular o crescimento de cabelo e pelos.
UY34636A (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
IN2014DN06169A (es)
ECSP17015154A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
SG10201900598TA (en) Factor viii formulation
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos
WO2012138731A3 (en) Activated nucleoside analog conjugates and methods of use thereof
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia
IN2015DN04074A (es)
BR112015020053B8 (pt) Composições para cuidado oral
MX2013008559A (es) Derivados de leptina.